Intra-Cellular Therapies(US:ITCI)2021-05-10 11:31Drug Development and Clinical Trials - CAPLYTA (lumateperone) was approved by the FDA for the treatment of schizophrenia in adults at a dosage of 42 mg/day, with a commercial launch initiated in late March 2020[134]. - Lumateperone is in Phase 3 clinical development for bipolar depression, with Study 402 showing a statistically significant improvement in depression (p=0.0206; effect size = 0.27) compared to placebo[135]. - Study 404 demonstrated that lumateperone 42 mg met the primary endpoint for improvement in depression (p<0.0001; effect size = 0.56) in both Bipolar I and Bipolar II patients[136]. - The FDA accepted supplemental new drug applications for lumateperone for bipolar depression treatment, with a PDUFA target action date set for December 17, 2021[137]. - The company is developing a long-acting injectable formulation of lumateperone, with a Phase 1 study initiated in December 2020 to evaluate its pharmacokinetics, safety, and tolerability[140]. - ITI-1284 ODT-SL, a new oral disintegrating tablet for elderly patients, is being developed for behavioral disturbances in dementia, with Phase 1 studies showing no serious adverse events[142]. - ITI-214, a PDE1 inhibitor, has shown favorable safety and tolerability in Phase 1/2 trials for Parkinson's disease, with plans to initiate a Phase 2 trial in the second half of 2021[143]. - ITI-333 is being evaluated for substance use disorders and associated comorbidities, with Phase 1 results expected in the second half of 2021[145]. Financial Performance - Total revenues for the three months ended March 31, 2021, were approximately $15.9 million, a significant increase from $1.1 million in the same period in 2020, driven primarily by net product sales of CAPLYTA[153]. - Net product sales for the three months ended March 31, 2021, were approximately $15.6 million compared to approximately $883,000 for the same period in 2020, reflecting a substantial growth in prescriptions since the product launch[164]. - Grant revenue for the three months ended March 31, 2021, was approximately $299,000, up from $201,000 in the same period in 2020, indicating continued support from government agencies[164]. - The company reported a net loss of $52.7 million for the three months ended March 31, 2021, compared to a net loss of $47.4 million in the same period in 2020[163]. - The company has raised approximately $1.6 billion through public and private offerings, grants, and other sources to fund operations through March 31, 2021[176]. - Product sales collected in the three months ended March 31, 2021, amounted to approximately $16.2 million, with expectations for growth going forward[176]. Expenses and Costs - Research and development expenses decreased to $15.1 million for the three months ended March 31, 2021, down approximately 5.9% from $16.0 million in the same period in 2020, primarily due to reduced manufacturing costs[167]. - Selling, general and administrative expenses increased to $52.6 million for the three months ended March 31, 2021, representing a 54.2% increase from $34.1 million in the same period in 2020, largely due to higher commercialization and marketing costs[171]. - Selling costs for the three months ended March 31, 2021, were $38.3 million, an 84% increase from $20.8 million in the same period in 2020, driven by increased marketing and sales-related labor costs[172]. - The cost of product sales was approximately $1.5 million for the three months ended March 31, 2021, compared to $70,000 for the same period in 2020, reflecting increased product sales volume[165]. - General and administrative expenses increased by 7.5% to $14.3 million for the three-month period ended March 31, 2021, compared to $13.3 million for the same period in 2020[174]. - The company expects research and development expenses to increase moderately as clinical trials for lumateperone progress, alongside anticipated costs for additional FDA approvals[161]. - The company expects selling, general and administrative costs to increase significantly in the remaining quarters of 2021 due to increased advertising and marketing efforts for the potential commercial launch of CAPLYTA[175]. Cash and Financing - As of March 31, 2021, the company had approximately $613.4 million in cash and cash equivalents, with net cash used in operations of $47.8 million during the three months ended March 31, 2021[180]. - The company plans to spend up to $300 million in 2021 primarily for the marketing and commercialization of CAPLYTA and advancing lumateperone-related programs[182]. - The company anticipates requiring additional financing in the future to continue funding operations and clinical trials for its product candidates[184]. - As of March 31, 2021, the company had approximately 5.2 million authorized shares of common stock available for future issuance[188]. - The company has incurred losses in every year since inception, except for 2011, with significant cash used in operations[184]. - The ongoing COVID-19 pandemic may negatively impact the company's commercialization efforts and clinical trials, potentially affecting liquidity[182]. - As of March 31, 2021, the company had cash, cash equivalents, marketable securities, and restricted cash totaling approximately $613.4 million[202]. - The company recognized an unrealized loss of approximately $0.2 million for the three months ended March 31, 2021, compared to an unrealized gain of approximately $0.4 million for the year ended December 31, 2020[202]. - The company does not have material exposure to high-risk investments such as mortgage-backed securities or auction rate securities within its money-market fund investments[202]. - The company relies on funds raised through other sources due to limited product revenues, with potential funding from further equity offerings[203]. - The company’s investment activities aim to preserve capital for funding operations, avoiding investments for trading or speculative purposes[202]. Risks and Uncertainties - The company’s estimates regarding expenses, future revenues, and capital requirements are subject to known and unknown risks and uncertainties[198]. - The COVID-19 pandemic may negatively impact the commercialization of CAPLYTA and the conduct of clinical trials[200]. - The company’s ability to attract collaborators with development, regulatory, and commercialization expertise is crucial for future product candidates[198]. - The company has plans to research, develop, and commercialize lumateperone and other product candidates[198]. - The company’s forward-looking statements are subject to risks that could cause actual results to differ materially from those anticipated[200].